Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...

On CRSP's fourth-quarter 2024 earnings call, investors' focus will likely be on the sales figure of Casgevy, its first marketed product.

Fintel reports that on February 3, 2025, HC Wainwright & Co. initiated coverage of CRISPR Therapeutics (NasdaqGM:CRSP) with a ...

Vertex Pharmaceuticals (VRTX) stock has performed strongly since the turn of the year, gaining 14.6% and vastly outperforming the healthcare ...

CRISPR Therapeutics AG (NASDAQ:CRSP) is a pioneer in gene-editing technology, using its patented gene sequencing platform to ...

CRISPR Therapeutics is a mid-stage biotech specializing ... the Board of CR The three-year partnership is another example of Vertex’s interest in improving on Casgevy, its CRISPR medicine ...

Lately, one of America's leading pharmaceutical companies can't catch a break from Wall Street. Shares of Vertex ...

Vertex and CRISPR Therapeutics have won the backing of NICE for their gene-editing therapy Casgevy as a treatment for the blood disorder beta thalassaemia, a few months after turning it down for ...

Some you might hold only temporarily, while others you own for decades. David Jagielski (Eli Lilly): A forever stock you can ...

Casgevy is a one-and-done treatment that Vertex is marketing and developing in partnership with CRISPR Therapeutics (NASDAQ: CRSP). As a treatment administered only once, it carries an enormous $2 ...

Vertex and CRISPR Therapeutics haven't started recording significant sales of Casgevy yet, but it could start contributing to their top lines soon. At the end of 2024, more than 50 authorized ...